Trial reportLeukemia2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).
Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention.Blood advances · 2021Trial
- Trial
- Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.International journal of hematology · 2026Review
- Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.Annals of hematology · 2026Article
- Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.Current oncology (Toronto, Ont.) · 2026Review
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- Allogeneic transplantation in adverse-risk acute myeloid leukemia: Challenges, strategies, and future directions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review.Annals of hematology · 2025Review
- Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas.Cells · 2025Review
- Review
- Review
- Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.Blood cancer journal · 2024Article
- Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.Frontiers in immunology · 2024Review
- Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse.Bone marrow transplantation · 2023Article
- Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.International journal of hematology · 2023Review
- New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia.Haematologica · 2023Review
- Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML.Cancer discovery · 2022Article
- Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.Journal of clinical medicine · 2022Review
- Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.Frontiers in oncology · 2022Review
- Maintenance therapy for AML after allogeneic HCT.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.